Clinical Trials
114 trialsNCT03217747 2026-05-05
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT01012817 2026-04-29
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02079740 2026-04-29
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02734290 2026-04-24
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
Phase 1/2 Active not recruiting
NCT01802632 2026-04-20
AURA
AstraZeneca
Phase 1/2 Completed
NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04266912 2025-11-25
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05525286 2025-11-17
CLAUDIO-01
Sotio Biotech Inc.
Phase 1/2 Terminated
NCT05847686 2025-11-05
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
University of Washington
Phase 1/2 Completed
NCT04208958 2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2 Completed
NCT05091346 2025-10-24
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT03711058 2025-09-16
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05578872 2025-08-26
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Anaveon AG
Phase 1/2 Completed
NCT02923349 2025-08-24
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
NCT02259231 2025-06-04
RTA 408 Capsules in Patients With Melanoma - REVEAL
Biogen
Phase 1/2 Completed
NCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT00317720 2025-04-30
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04875806 2025-04-22
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Terminated
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT03829501 2025-04-02
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Phase 1/2 Terminated
NCT03024437 2025-03-20
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Phase 1/2 Terminated
NCT04761198 2025-03-17
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1/2 Completed
NCT03747484 2025-03-06
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT04574583 2025-02-03
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03601897 2024-12-27
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT03717415 2024-12-27
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT03436563 2024-11-27
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT03345485 2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2 Completed
NCT04683939 2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
Phase 1/2 Terminated
NCT04521621 2024-10-01
V937-013
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00819169 2024-08-20
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NantCell, Inc.
Phase 1/2 Terminated
NCT03127098 2024-08-06
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT04408599 2024-07-25
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Terminated
NCT01326871 2024-06-25
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience
Phase 1/2 Completed
NCT01670994 2024-06-18
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
Phase 1/2 Terminated
NCT04161391 2024-06-13
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT02235701 2024-05-29
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
ImmunityBio, Inc.
Phase 1/2 Completed
NCT05071183 2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT03665285 2024-03-08
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Completed
NCT03257722 2024-02-28
PIL
Augusta University
Phase 1/2 Terminated
NCT02030067 2023-12-06
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Processa Pharmaceuticals
Phase 1/2 Completed